CRISPR gene editing startup Beam Therapeutics plans $100M IPO

Mere months after raising $135 million from investors, another gene editing startup co-founded by MIT researcher Feng Zhang is preparing to go public.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.